[S-48-2] アルツハイマー病における病原性タンパク質の伝播と治療介入
In recent years, many clinical trials for Alzheimer's disease (AD) have ended in disappointment. Now it's time to rethink strategy to defeat AD. In this symposium, researchers at the vanguard of AD basic research will introduce their recent remarkable work, including elucidation of AD pathomechanisms, generation of AD animal models, and establishing new concepts of therapies and biomarkers utilizing cutting-edge technologies. We believe that talk in this session will provide neurologists important insights to gain a better understanding of AD.
Takeshi Iwatsubo is a Professor of Neuropathology at the University of Tokyo. He was graduated from Univ of Tokyo and trained in neurology and neuropathology. He has contributed to Alzheimer’s and Parkinson disease research, demonstrating that A42 is the initially deposited species in brain amyloid, and elucidating the process of -secretase complex formation. He identified -synuclein is a component of Lewy bodies. On the clinical front, Iwatsubo has been the principal inversitgators of Japanese ADNI, the A4 study in Japan, and the Japanese Trial Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (J-TRC-PAD), aiming at preventing AD before symptoms begin.
抄録パスワード認証
パスワードは抄録集に記載してあります。